Stem Cell Clinic

Translational Regenerative Medicine Market: Immunotherapy is projected to be the fastest growing segment during the forecast period – BioSpace

Regenerative medicine is a segment of translational research in molecular biology and tissue engineering. It involves the process of regeneration of human cells, tissues, or organs to re-establish their normal functions through stimulation of bodys repair system. They are widely used in the treatment of many degenerative disorders occurring in the areas of dermatology, orthopedic, cardiovascular and neurodegenerative diseases. Stem cell therapy is the available tool in the field of translational regenerative medicine. It has gained importance in the past few years as it is a bio-based alternative to synthetic options. Stem cells have high power of regeneration. Hence, these enable production of other cells in the body. This has increased demand for stem cell therapy in the treatment of degenerative diseases. Currently, stem cell therapy has applications in the treatment of diseases such as autism, cancer, retinal diseases, heart failure, diabetes, rheumatoid arthritis, Alzheimers. Extensive research is being carried out on stem cell therapy. The Centre for Commercialization of Regenerative Medicine (CCRM) has reported around 1900 active clinical trials undergoing currently. It also reported 574 active industry-sponsored cell therapy clinical studies, 50 of these are in phase 3 development. Hence, stem cell therapy is projected to contribute to the growth of the translational regenerative medicine market. However, ethical issues in the use of embryonic stem cells is likely to restrain the market.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30440

Rising prevalence of degenerative diseases, aging population, rapid growth of emerging countries, and technical advancements in developed countries are the major factors fueling the growth of the translational regenerative medicine market.

The global translational regenerative medicine market has been segmented based on product type, therapy, application, and region. In terms of product type, the market has been categorized into cellular and acellular. The cellular segment dominated the global market in 2016. Based on therapy, the global translational regenerative market has been segmented into cell therapy, gene therapy, immunotherapy, and tissue engineering. Immunotherapy is projected to be the fastest growing segment during the forecast period. In terms of application, the market has been segmented into orthopedic & musculoskeletal, cardiology, diabetes, central nervous system diseases, dermatology, and others. Cardiology and orthopedic & musculoskeletal are anticipated to be the fastest growing segments of the global translational regenerative medicine market. In terms of region, the global translational regenerative medicine market has been segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominated the global regenerative medicine market owing to a large number of leading companies and expansion of research and development activities in the U.S. Increased medical reimbursement and advanced health care also drive the market in the region. Orthopedic is the leading application segment contributing to the growth of the market in the region. Asia Pacific is forecasted the huge growth because of large consumer pool, rising income, and health care expenditure. However, the market in Asia Pacific could face challenges such as high cost of bio-based medicines and stringent regulatory policies.

Request for Analysis of COVID-19 Impact on Translational Regenerative Medicine Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=30440

The global translational regenerative medicine market is dominated by key players such as CONMED Corporation, Arthrex, Inc., Organogenesis, Inc., Nuvasive, Inc., Osiris Therapeutics, Inc., Celgene Corporation, Brainstorm Cell Therapeutics Inc. and Medtronic.

Pre Book Translational Regenerative Medicine Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=30440&ltype=S

The following regional segments are covered comprehensively:

Read more information here:

https://www.transparencymarketresearch.com/translational-regenerative-medicine-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit Bhisey Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read this article:
Translational Regenerative Medicine Market: Immunotherapy is projected to be the fastest growing segment during the forecast period - BioSpace

Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies – PRNewswire

VANCOUVER, BC, Feb. 10, 2021 /PRNewswire/ --Notch Therapeutics, Inc., a biotechnology company developing renewable, induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, announced today the closing of an oversubscribed U.S. $85 million Series A financing. The financing was led by an exclusively healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Inc. (NASDAQ: ALLO), Lumira Ventures, and CCRM Enterprises Holdings Ltd., an affiliate of Centre for Commercialization of Regenerative Medicine (CCRM); along with new investors EcoR1 Capital, a undisclosed leading global investment firm, Casdin Capital, Samsara BioCapital, and Amplitude Ventures. Proceeds from the financing will support the continuing development of Notch's portfolio of iPSC-derived T cell therapeutic product candidates and clinical readiness of the company's proprietary Engineered Thymic Niche (ETN) platform. The financing will also enable Notch to expand its team to support the company's future growth, including establishing operations in Seattle, in addition to the company's existing operations in Vancouver and Toronto.

"We are gratified to have the confidence of this exceptional group of investors and have them share in our vision that our platform can be game-changing for cell therapies by easing cell manufacturing and broadening their clinical and commercial potential," said David Main, President and Chief Executive Officer of Notch. "The level of interest in this financing round enabled us to far exceed our original capital-raising goals. With this support, Notch is well positioned to support our partners and advance development of our initial cell therapy products for patients with cancer."

Notch is applying its scalable Engineered Thymic Niche (ETN) technology platform to develop homogeneous and universally compatible, stem cell-derived cell therapies. To date, Notch has assembled a world-class scientific team and built a fully integrated, tightly controlled platform for generating and editing immune cells from clonal stem cells to enable development of a broad range of T cell therapeutics. Notch has an existing partnership with Allogene Therapeutics to apply Notch's proprietary ETN platform to develop CAR-targeted, iPSC-derived, off-the-shelf T cell or natural killer (NK) cell therapies for hematologic cancer indications.

"We have great confidence in Notch's high-caliber management team and the rigorous science underlying its research programs," said David Chang, M.D., Ph.D., President, Chief Executive Officer, and Co-Founder of Allogene and a member of the Notch Board of Directors. "We are impressed by the company's innovation and accomplishments and pleased to continue our support of Notch as the company advances the development of a new generation of cell therapies for cancer and other immune disorders."

About Notch Therapeutics (www.notchtx.com) Notch is developing a pipeline of cellular immunotherapies originating from pluripotent stem cells that are specifically engineered to address the underlying biology of complex disease systems. The company has unlocked the ability for large-quantity production of T cells and other cells from any source of stem cells to bring best-in-class cell therapies for cancer and other immune disorders to thousands of patients. The core of the Notch platform is the Engineered Thymic Niche (ETN), which enables precision control of cell fate during the differentiation and expansion of stem cells in suspension bioreactors without the need for feeder cells or serum. The ETN has the potential to generate immunotherapies with decreased variability, increased potency, and engineered improvements. The technology was invented in the laboratories of Juan-Carlos Ziga-Pflcker, Ph.D. at Sunnybrook Research Institute and Peter Zandstra, Ph.D., FRSC at the University of Toronto. Notch was founded by these two institutions, in conjunction with MaRS Innovation (now Toronto Innovation Acceleration Partners) and the Centre for Commercialization of Regenerative Medicine (CCRM), which initially incubated the company.

Contact:Mary Moynihan M2Friend Biocommunications 802-951-9600 [emailprotected]

SOURCE Notch Therapeutics

Notch Therapeutics

Here is the original post:
Notch Therapeutics Closes $85 Million Series A Financing to Develop Pipeline of Renewable Stem Cell-Derived Cancer Immunotherapies - PRNewswire

Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First Off-the-shelf Genomic Medicines – Business Wire

BOSTON--(BUSINESS WIRE)--Ensoma, a company expanding the curative power of genomic medicine by pioneering a next-generation in vivo approach, today launched with a $70 million Series A financing led by co-founder and seed investor 5AM Ventures, with participation from F-Prime Capital, Takeda Ventures, Viking Global Investors, Cormorant Asset Management, RIT Capital Partners, Symbiosis II, LLC, and Alexandria Venture Investments. In addition to an equity investment of $10 million in the Series A financing, Takeda Pharmaceutical Company Limited (Takeda) and Ensoma have entered into a strategic collaboration with the potential for upfront and preclinical research payments totaling $100 million as part of a strategic collaboration worth up to $1.25 billion, announced in a separate press release this morning.

The foundation of the companys platform its Engenious vectors is based on over two decades of academic and clinical research generated by scientific co-founders and renowned experts, Hans-Peter Kiem, M.D., Ph.D., of Fred Hutchinson Cancer Research Center, and Andr Lieber, M.D., Ph.D., of University of Washington School of Medicine. The company will be led by biotechnology industry veterans with demonstrated track records in innovative therapeutic modalities, including gene therapy and editing, across an array of disease areas, including rare disease, hematology and oncology.

Ensomas Engenious vectors are designed to deliver a diverse range of genome modification technologies including those that require a high level of packaging capacity directly to hematopoietic stem cells (HSCs) or the various cell types that arise from these cells, such as T cells, B cells and myeloid cells. The companys vectors are optimized to work without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensomas therapies will be designed to be delivered via single injection in diverse environments, including outpatient and areas where access to sophisticated healthcare systems may be limited.

With the launch of Ensoma, we aspire to bring innovative new treatments to patients in a way that is accessible for all, said Paula Soteropoulos, executive chairman of Ensoma. Because our in vivo therapies do not require prior conditioning or stem cell donors, we hope to deliver them as off-the-shelf treatments to address diseases both rare and common dramatically simplifying the logistics of scaling production and reducing patient and healthcare-system burden. Every person, no matter where they are in the world, should have access to the innovative technologies that are changing the way we treat disease.

Engenious Vectors

Ensomas Engenious vectors are specially engineered adenovirus vectors devoid of any viral genome and minimal pre-existing immunity, thus minimizing the chance of an immune response and freeing up ample storage space up to 35 kilobases (kb) of DNA packaging capacity to deliver a diverse range of genome modification technologies. Also known as therapeutic cargo, these technologies may include, separately and in combination, the following:

These approaches enable Engenious vectors to engineer various erythroid, lymphoid (e.g., T cells, B cells) and myeloid (e.g., macrophages, microglia) cell types, with great precision and vast therapeutic potential. Addressable indications range from rare monogenic diseases to broader diseases such as oncology, autoimmunity and infectious diseases via precision, off-the-shelf engineering of the immune system.

Given the highly specific nature of these technologies, Ensomas Engenious vectors enable preferential targeting of HSCs inside the body. Additionally, Ensomas founders have developed an in vivo selection system that can increase the population of genetically modified HSCs, if needed. This proprietary approach enables precise titration to lasting therapeutic levels without the need to re-dose patients, bypassing the immunogenic challenges associated with re-dosing for some other gene therapy modalities.

Ensomas Engenious platform has been extensively validated in numerous preclinical models with a range of genome editing technologies, demonstrating robust genetic modification of bone marrow HSCs and stable long-term expression of therapeutic proteins in small and large preclinical models.

There have been tremendous advancements in technologies to precisely target, genetically edit and modify human disease. However, many of these tools pose delivery challenges; some lack the ability to reach the right cells within the body, while others lack the ability to broadly reach significant numbers of patients due to complex procedures and supply chain challenges, said Kush M. Parmar, M.D., Ph.D., founding chief executive officer of Ensoma. Ensomas scientific approach allows us to do what hasnt been done beforeto make the curative power of genomic medicine and stem cell technology portable so they may be administered in low-resource and outpatient settings for the very first time.

Leadership & Scientific Founders

Ensoma was founded by and incubated within the 4:59 Initiative, the company creation engine of 5AM Ventures. The companys scientific co-founders include Dr. Hans-Peter Kiem, an oncologist and world-renowned pioneer in gene-editing technologies, including stem cell and gene therapies, from Fred Hutch, who also serves as vice president of the American Society of Gene & Cell Therapy and chief scientific and clinical advisor for Ensoma; and Dr. Andr Lieber, an accomplished academic researcher and professor of medicine, Division of Medical Genetics, UW School of Medicine, who has studied the biological and translational aspects of human adenoviruses for more than two decades. Ensoma is based on an exclusively licensed portfolio of technologies developed by the Fred Hutch lab of Dr. Kiem and the University of Washington lab of Dr. Lieber that enable in vivo genome engineering and gene therapy advances of HSCs for therapeutic use in blood diseases.

Following more than 20 years of academic and clinical research, Ensoma has assembled an exceptional team to boldly forge a new era of genomic medicine in vivo, said Bihua Chen, founder and portfolio manager at Cormorant Asset Management. The company is moving swiftly to accelerate and broaden the therapeutic potential of its approach, and I am confident they have the right team and the right technology to potentially bring life-changing, curative therapies within reach for people all over the world.

Additional details surrounding company leadership, including its board of directors, are as follows:

Ensoma has also named its scientific advisory board, which may be viewed here.

About 5AM Ventures

Founded in 2002, 5AM actively invests in next-generation biotech companies. With approximately $1.5 billion raised since inception, 5AM has invested in 89 companies. For more information, please visit http://www.5amventures.com.

About the 4:59 Initiative

The 4:59 Initiative is the internal company creation engine at 5AM Ventures that helps discover, incubate, and fund breakthrough science. The 4:59 team provides hands-on scientific, strategic, and operational support, working closely with academics and entrepreneurs to advance breakthrough science and establish proof-of-concept data to enable a clear path to transformative therapies for patients.

Read the original post:
Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First Off-the-shelf Genomic Medicines - Business Wire

Global Biopreservation Market Is Expected to Reach USD 7.67 Billion by 2028 : Fior Markets – GlobeNewswire

February 10, 2021 13:00 ET | Source: Fior Markets

Newark, NJ, Feb. 10, 2021 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, theglobal biopreservation market is expected to grow from USD 3.55 billion in 2020 to USD 7.67 billion by 2028, at a CAGR of 10.1% during the forecast period 2021-2028.

Some of the critical factors that are fuelling the growth of the global biopreservation market are technological advancements in the field of biopreservation, increasing private as well as government investment in R&D, increasing health care expenditure, and a rising regenerative medicine demand due to the expanding rate of lifestyle diseases. Biopreservation is crucial for the success of distinct commercial & clinical applications of emerging cell-based technologies. Advancements in biopreservation such as next-gen cryopreservation solutions, integration & design with nanoscale technology, and standardization of hypothermic storage are leading to important long period preservation of complex tissues & organs in transplantation & regenerative medicine. The Cooperative Human Tissue Network (CHTN) was set up by the National Cancer Institute, which uses collective efforts to advance bio-banking.

With the outbreak of a global pandemic, many have faced salary cuts and job losses. Covid-19 has become a threat to the entire world's economy and has negatively impacted all kinds of markets, including the biopreservation market. With less disposable income and broken supply chains, the market's growth is expected to slow down. Research activities all over the world had been stopped due to lockdowns. The emergence of competing technologies like room temperature storage technology has a negative effect on the market. Another challenge is the strict regulations that governments have put up regarding biopreservation.

DOWNLOAD FREE SAMPLE REPORT AThttps://www.fiormarkets.com/report-detail/419199/request-sample

Key players operating in the global biopreservation market include BioCision, Custom Biogenic Systems, Panasonic Biomedical, Thermo Fisher Scientific, VWR International, Atlanta Biologics, BioLife Solutions, Chart MVE Biomedical, LabVantage Solutions, and Taylor-Wharton Cryogenics, among others. To gain a significant market share in the global biopreservation market, the key players are now focusing on adopting strategies such as product innovations, mergers & acquisitions, recent developments, joint ventures, collaborations, and partnerships. Thermo Fisher Scientific and Taylor-Wharton Cryogenics are some of the biggest players in the global biopreservation market.

The equipment segment dominated the market and held the largest market share of 61.8% in the year 2020

The product segment consists of laboratory information management system, media, and equipment. The equipment segment dominated the market and held the largest market share of 61.8% in the year 2020. The extensive use of equipment in plasma, DNA, tissue, and stem cell research is driving the growth of this segment. Advanced equipment is necessary for high cost-efficiency, low maintenance and adequate storage capacity.

The tumor cells segment dominated the market and held the largest market share of 22.45% in the year 2020

Based on cell provider, the global market has been divided into tumor cells, hESC (human Embryonic Stem Cell), CD19+, CD34+, iPSC (Induced Pluripotent Stem Cells), MSC (Mesenchymal stem cells), and others. The tumor cells segment dominated the market and held the largest market share of 22.45% in the year 2020 due to its numerous applications in R&D, diagnosis, and cancer treatment. Tumor cells act as effective biomarkers in different types of cancers like breast, prostate, and colon cancer.

The bio-banking segment dominated the market and held the largest market share of 58.36% in the year 2020

On the basis of application, the biopreservation market has been segmented into bio-banking, regenerative medicine, and drug discovery. The bio-banking segment dominated the market and held the largest market share of 58.36% in the year 2020 due to the various advantages of stem cell preservation. The expanding number of egg banks and sperm banks around the world boost the growth of this segment.

Browse full report with TOC athttps://www.fiormarkets.com/report/biopreservation-market-by-product-laboratory-information-management-system-419199.html

Regional Segment Analysis of the Biopreservation Market

On the basis of geography, the global biopreservation market has been classified into North America, Europe, South America, Asia Pacific, and Middle East and Africa. The North America region accounted for the major market share of 46.9% in the year 2020 and is anticipated to grow throughout the projected period. The large share of this segment is attributed to key factors such as the growing geriatric population, advancing drug development & biomedical research, an increasing number of patients needing specialized treatment for lifelong diseases, and the presence of significant pharmaceutical & pharmaceutical companies in the region. On the other hand, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period 2021-2028. This growth is owing to factors like an increasing patient base and rising government investments in biomedical research & development.

Request for Customization:https://www.fiormarkets.com/enquiry/request-customization/419199

About the report:

The global biopreservation market is analyzed on the basis of value (USD Billion). All the segments have been analyzed on a global, regional, and country basis. The study includes the analysis of more than 30 countries for each segment. The report offers an in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The study includes porter's five forces model, attractiveness analysis, raw material analysis, and competitor position grid analysis.

For Instant Purchase:https://www.fiormarkets.com/checkout.html?reportid=419199&type=single

Customization of the Report:

The report can be customized as per client requirements. For further queries, you can contact us onsales@fiormarkets.comor +1-201-465-4211. Our executives will be pleased to understand your requirements and offer you the best-suited reports.

About Fior Markets

Fior Markets is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports. Fior Markets deploys a wide range of regional and global market intelligence research reports including industries like technology, pharmaceutical, consumer goods, food and beverages, chemicals, media, materials and many others. Our Strategic Intelligence capabilities are purposely planned to boost your business extension and elucidate the vigor of diverse industry. We hold distinguished units of highly expert analysts and consultants according to their respective domains. The global market research reports we provide involve both qualitative and quantitative analysis of current market scenario as per the geographical regions segregated and comprehensive performance in different regions with global approach. In addition, our syndicated research reports offer a packaged guide to keep companies abreast of the upcoming major restyle in their domains. Fior Markets facilitates clients with research analysis that are customized to their exact requirements, specifications and challenges, whether it is comprehensive desk research, survey work, composition of multiple methods, in-detailed interviewing or competitive intelligence. Our research experts are experienced in matching the exact personnel and methodology to your business need.

Contact Us

Avinash D Head of Business Development Phone:+1-201-465-4211 Email:sales@fiormarkets.com Web:www.fiormarkets.com

To Read Top Industries Reports, Visit our Affiliated Website: https://www.marketquest.biz

Related Reports

Histone Deacetylase (HDAC) Inhibitors Market - https://www.fiormarkets.com/report/histone-deacetylase-hdac-inhibitors-market-by-application-oncology-399164.html Anthrax Vaccines Market - https://www.fiormarkets.com/report/anthrax-vaccines-market-by-vaccine-type-live-vaccines-399166.html Antifungal Drugs Market - https://www.fiormarkets.com/report/antifungal-drugs-market-by-drug-class-azoles-echinocandins-407129.html Bovine Lactoferrin Market - https://www.fiormarkets.com/report/bovine-lactoferrin-market-by-type-freeze-dried-and-milled-417794.html

Read the original post:
Global Biopreservation Market Is Expected to Reach USD 7.67 Billion by 2028 : Fior Markets - GlobeNewswire

Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi…

Stem Cell Therapy Market

Stem Cell Therapy Market Projections (2020-2029): The Global market Stem Cell Therapy theologizes is the most recent of the world business market curves. The report prospects the current and frequent collectors, technological innovations, product supplementation, and their representation of performance broadly across the foreign market.

Thisphenomenalstudy on world-widebusiness includes the results of vital primary and secondary resources. These research findings are accepted by the companys skilled analysts and experts, providing rich in-depth information to associated partners, appraisers as well as captains of the industry.

Get a Sample Copy of this Report @ https://www.regalintelligence.com/request-sample/148234

Prominent players in the industry covered in the report:

Osiris Therapeutics, NuVasive, Chiesi Pharmaceuticals, JCRPharmaceutical, Pharmicell, Medi-post, Anterogen, Molmed, Takeda (TiGenix)

Market split by Type, can be divided into: Autologous Allogeneic

Market split by Application, can be divided into: Musculoskeletal Disorder Wounds & Injuries Cornea Cardiovascular Diseases Others

Market split by Sales Channel, can be divided into: Direct Channel Distribution Channel

Ourstudypasses through ahaven ofprofound qualitative and quantitativeresearch by industryexperts andprofessionals.Within the reportcontributes a broadperceptionof thepast as well ascurrent marketvista,which implies future statistics and prospects in position with the technical developments over time. Furthermore, the report includes and provides analyses of demand and supply, microeconomic and macroeconomic elements, administrative components and growth indices through the Stem Cell Therapy marketplace. The report outlines keytacticsutilized bykey market participants.

Reach us to quote the effective price of this report (UPTO 50% OFF) @ https://www.regalintelligence.com/check-discount/148234

This report provides an accurate understanding and discovery of key geographic areas underway with market Stem Cell Therapy, including critical segments and additional segments.The report sets out aspects of territorial growth and the size and scope of the market. Additionally, the report also deals with trading information such as business range, cost and revenue margin as well as gross value. However, this understanding assists readers in the conduct of consumer experts as well as major tactic to reach market share.

Substantivebeneficiaries:

Additional Information:

This reportcontributes to the following:

Important questions answered within this report:

About Us: We, Regal Intelligence, aim to change the dynamics of market research backed by quality data. Our analysts validate data with exclusive qualitative and analytics driven intelligence. We meticulously plan our research process and execute in order to explore the potential market for getting insightful details. Our prime focus is to provide reliable data based on public surveys using data analytics techniques. If you have come here, you might be interested in highly reliable data driven market insights for your product/service,reach us here 24/7.

Mention your Queries here to Get a Call from Our Industry Expert @sales@regalintelligence.com

Contact Us: Regal Intelligence: http://www.regalintelligence.com Ph no: +1 231 930 2779 (U.S.) | +44 141 628 8787 (UK)

Read more here:
Stem Cell Therapy Market Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast By 2029: Osiris Therapeutics, NuVasive, Chiesi...

Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater…

FOSTER CITY, Calif., HANGZHOU, China and HOUSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, today announced an exclusive collaboration and license agreement for the development and commercialization of tegavivint in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China.

Tegavivint is a potent and selective inhibitor of nuclear -catenin that works through binding to TBL1 (Transducin Beta-like Protein One), a downstream target in the Wnt-signaling pathway. Iterion is pursuing the development of Tegavivint for the treatment of cancers where nuclear -catenin signaling is known to play a role. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors.

As a potent and selective small molecule targeting the Wnt-signaling pathway, Tegavivint is an ideal addition to our clinical development pipeline, said Guo-Liang Yu, Ph.D., Chief Executive Officer of Apollomics. The preclinical work has demonstrated that the differentiated mechanism of action may be applicable in several indications as both a monotherapy and a combination treatment. We look forward to working with the Iterion team to expand development in Greater China.

Under the terms of the agreement, Apollomics will be responsible for clinical development and commercialization in Greater China. Apollomics and Iterion will form a joint development committee to ensure ongoing collaboration of Tegavivint across indications and geographies. Iterion has received an initial cash payment for ongoing research and development costs in connection with the companys global development of Tegavivint. Iterion is also eligible to receive potential development and sales milestone payments, as well as tiered royalties on net sales. Apollomics will be responsible for all costs related to development and commercialization activities for Tegavivint in Greater China.

Rahul Aras, Ph.D., President and Chief Executive Officer, Iterion Therapeutics, added, As we explore multiple indications for Tegavivint in the U.S., including desmoid tumors, acute myeloid leukemia, non-small cell lung cancer, and pediatric cancers, we are excited to partner with Apollomics to expand its development and potential commercialization in Greater China. With Apollomics oncology focus and growing footprint in China, they are the partner of choice to successfully advance Tegavivint for cancer patients in this region.

About Tegavivint

Tegavivint is a potent and selective inhibitor of nuclear -catenin that binds to TBL1 (Transducin eta-like Protein One), a downstream target in the Wnt-signaling pathway. Targeting TBL1 may enable specific silencing of Wnt-pathway oncogenic gene expression without affecting other necessary cellular functions that are disrupted when targeting higher up the Wnt-pathway. This avoids toxicity issues common to other drugs in this pathway.

Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in progressive desmoid tumors. Desmoid tumors, a rare type of sarcoma for which there is no currently approved therapy, are driven primarily by nuclear -catenin signaling and, thus, present an optimal indication for demonstrating the drugs mechanism of action as the company pursues additional clinical programs. Tegavivint has also demonstrated anti-tumor activity in multiple pre-clinical models, including acute myeloid leukemia (AML) and non-small cell lung cancer (NSCLC).

About Iterion Therapeutics

Iterion Therapeutics is a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics. The company's lead product, Tegavivint, is a potent and selective inhibitor of nuclear -catenin, an oncology target implicated in cell proliferation, differentiation, immune evasion and stem cell renewal. Research demonstrating anti-tumor activity in multiple pre-clinical models indicate that Tegavivint has the potential for clinical utility in multiple cancer types. Tegavivint is currently the subject of a Phase 1/2a clinical trial in patients with progressive desmoid tumors. Iterion is also pursuing development in additional cancers where nuclear -catenin signaling has been shown to play a role, including acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers, including sarcomas, lymphoma and other solid tumors. This research/clinical trial was supported with a$15.9 milliongrant from the Cancer Prevention & Research Institute ofTexas. For more information on Iterion, please visit https://iteriontherapeutics.com.

About Apollomics, Inc.

Apollomics, Inc. is an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The companys existing pipeline consists of several development-stage assets, including novel, humanized monoclonal antibodies that restore the bodys immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. For more information, please visitwww.apollomicsinc.com.

Iterion Therapeutics Contact:

Tiberend Strategic Advisors, Inc. Ingrid Mezo(Media) 646-604-5150 imezo@tiberend.com

Apollomics Contacts:

Investor Contact: Wilson W. Cheung Chief Financial Officer (650) 209-4436 wcheung@apollomicsinc.com

U.S. Media Contact: Remy Bernarda Corporate Communications (415) 203-6386 remy.bernarda@apollomicsinc.com

More here:
Apollomics, Inc. and Iterion Therapeutics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Tegavivint in Greater...

2020 Outlook on the Global Singlecell Technology Industry – Market Size was Over $800 Million in 2019 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Singlecell Technology Market Landscape 2020" report has been added to ResearchAndMarkets.com's offering.

The global single cell technology (SCT) market has emerged since 2014. There are over 43 companies with various 49 SCT products commercialized worldwide, and over 15 pre-commerce-stage startups are lined up and keep increasing. The market size is over $800 M in 2019, at a CAGR of ~24%.

The market is expected to grow significantly by the growing awareness of the single cell projects among biology communities, the growth of precision medicine and diagnostic industry, the antibody therapeutic drug development, the entry of new players, etc.

However, the high cost of the equipment, the requirement of in-person demo, various remaining technical challenges & defaults of the products that rushed into the market too early, and lack of interdisciplinary expertise on the customer sides could limit the market growth rates. Acquisitions and partnerships are actively seen as for most of the competitive technology industry.

The majority (~60%) of the market players are small-sized startup companies with under 100 employees, however, the market share is highly concentrated on four major companies (BD, 10x genomics, Fluidigm, and Berkeley light), yet this market share can change as the market is expanding and more new players are entering, more differentiation among players is expected.

Primarily, the SCT market has a complex market structure characterized by its wide range of technology mixtures and various types of users across various life science research fields. The general functionalities of the SCT are: single cell (SC) isolation, SC-sequencing, SC-protein analysis, or SC-focused manipulation. Among those, the first two category products (SC-isolation and SC-sequencing) account for ~72% of the market.

SCT can be applied in most of the life science application as it is defined by any biological science experimentation that handles and generate single cell resolution data. Stem cell research and cancer research are the fields of studies that have adapted SCT the most, and immunology and neurobiology also have a growing need in SCT. The market is categorized by the core technologies (11 categories) and by the applications (5 categories).

The core technology categories include conventional cell picking, limited dilution, FACS, and laser capture microdissection (LCM) technologies, but also novel technologies for automatic single cell picking, automatic single cell dispensing, microwell-based single cell isolation/analysis, microfluidic chip based-single cell analysis, droplet microfluidics-based, novel cytometry, and cell manipulation. The five market application categories include SC-isolation, SC-DNA/RNA sequencing, cell line development, protein or functional analysis, and drug discovery & diagnostics.

Companies Mentioned

Key Topics Covered:

Preface

Executive Summary

Part One: the Market and Strategy Perspectives

Chapter 1 Market Structure and Market Size

1.1 Market Structure

1.2 Market Size

1.3 Market's Dynamic Growth & Restraint Factors

Chapter 2 Projecting Strategic Plans

2.1 Strategic Moves by Current SCT Companies

2.2 Market Innovating Strategy

Part Two: Biology and Its Evolution- Market from the Customers Perspective

Chapter 3 Single Cell Biology by -Omics and Field of Study

3.1 Single Cell Biology: Physics and Engineering Meet Biology

3.2 Single Cell Biology by -Omics Fields

3.3 Single Cell Biology by Field of Studies

Chapter 4 Understanding the Customer and Their Workflow

4.1 Understand the Customer's Workflow

4.2 Understand the Customer Experience Cycle

Part Three: Market from the Technology Providers Perspective

Chapter 5 Market Segments by Technology

5.1 Overview

5.2 Manual Picking

5.3 Limited Dilution

5.4 FACS: Fluorescence Activated Cell Sorter

5.5 Laser Capture Microdissection (LCM)

5.6 Automatic Single Cell Pickers

5.7 Single Cell Dispensing

5.8 Microwell Based Single Cell Isolation

5.9 Microfluidics Chip-Based Single Cell Analysis

5.10 Droplet Microfluidics

5.11 New Type of Cytometry and Spectroscopy

5.12 Fluidics and Cell Manipulation

Chapter 6 Market Segments by Applications

6.1 Overview

6.2 SC-Dna and Rna Sequencing

6.3 Cell Line Development

6.4 Protein or Functional Analysis

6.5 Drug Discovery and Diagnostics

Chapter 7 Emerging Early Stage SCT Startup Companies

7.1 Emerging Early Stage SCT Startup Companies

or more information about this report visit https://www.researchandmarkets.com/r/6q7yf9

See the original post:
2020 Outlook on the Global Singlecell Technology Industry - Market Size was Over $800 Million in 2019 - ResearchAndMarkets.com - Business Wire

Stem Cell Cryopreservation Equipments Market Size Report: Strategies of Key Manufacturers, Project Investment of New Industries: Chart, Worthington…

TheStem Cell Cryopreservation Equipments Marketincludes numbers for all the segments at the country level for past, current and coming years. This report provides comprehensive market information through detailed segmentation along with segmental market size and forecasts, growth rates, market dynamics, structure, it also provides an overview of the development of the industry, market situation, and trends.

The report covers a detailed analysis of players and market strategies, a detailed analysis of growth factors that are critical for existing market participants as well as new market players. It provides information on new market opportunities and the future with main drivers and restraints of the market to support the decision in a cost-effective business solution.

>>>Get Sample PDF Copy:https://www.worldwidemarketreports.com/sample/562010

The report introduces Stem Cell Cryopreservation Equipments basics:

Definitions, categories, software, and market reviews; Product Features; Manufacturing process; Cost arrangement, development, and its aftermath. Subsequently, it studied the requirements of the international major Stem Cell Cryopreservation Equipments industry market, for example, the price, profit, capacity, production, distribution, market and demand growth and forecasting of goods, etc. In the long run, the report introduced a new Stem Cell Cryopreservation Equipments SWOT analysis. Feasibility, and revenue investigation.

Stem Cell Cryopreservation Equipments Report by Type, Application with Geography The International Forecast for 2026 is actually an efficient and comprehensive research study on the worlds major regional economy states, focusing on key areas such as the United States, Canada Does, Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden, Poland, Belgium, China, Japan, South Korea, Australia, India, Taiwan, Indonesia, Thailand, Philippines, Malaysia, Brazil, Mexico, Argentina, Colombia, Chile, Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of the World.

This Report covers Leading Companies associated in Stem Cell Cryopreservation Equipments:Chart, Worthington Industries, Cesca Therapeutics, Shengjie Cryogenic Equipment, Sichuan Mountain Vertical, Qingdao Beo

Importance of this Stem Cell Cryopreservation Equipments

1. Industry Synopsis of the International Stem Cell Cryopreservation Equipments Market; 2. Global Stem Cell Cryopreservation Equipments Market Company Manufacturer Overview and Profile; 3. Technical data and economy manufacturing plants; 4. Capacity, revenue, and production analysis; 5. Region, Manufacturers and Types by Cost, Price, Gross, and Gross Fiscal Analysis Stem Cell Cryopreservation Equipments; 6. Sales price analysis of Stem Cell Cryopreservation Equipments business share by volume, price, and valuation of consumption, type, and software; 7. Supply, Import, Export, and Presence Analysis of Stem Cell Cryopreservation Equipments Market; 8. Significant manufacturer analysis of Stem Cell Cryopreservation Equipments market size; 9. Marketing Trader or Distributor Analysis; 10. Industry Chain Analysis; 11. Development Trend Analysis of Stem Cell Cryopreservation Equipments Market Trends; 12. Stem Cell Cryopreservation Equipmentss new project feasibility analysis

By Types

Liquid Phase, Vapor Phas

By Application

Cord Blood Stem Cell Cryopreservation, Other Stem Cell Cryopreservatio

>>>Ask Our Industry Expert:https://www.worldwidemarketreports.com/quiry/562010

General studies include Stem Cell Cryopreservation Equipments value chain analysis that provides an understanding of key players from the distribution chain, particularly from manufacturers to end-users. In addition, the report supplies the Stem Cell Cryopreservation Equipments International Economic Competition with the help of Porters analysis of the five forces.

Also, Global Stem Cell Cryopreservation Equipments Market includes the following features with detailed study of each

Key Players: The report provides a company outline for a good number of the leading players of the global Stem Cell Cryopreservation Equipments market. It brings to light their current and future Stem Cell Cryopreservation Equipments market development taking into account their price, gross margin, revenue, production, service sectors, production sites, and other factors.

Stem Cell Cryopreservation Equipments Market Dynamics: The report shares important information on impact factors, Stem Cell Cryopreservation Equipments market drivers, challenges, opportunities, and market trends as part of market dynamics.

Global Stem Cell Cryopreservation Equipments Market Forecast: Readers are provided with production and revenue forecasts for the Stem Cell Cryopreservation Equipments market, production and consumption forecasts for regional markets, production, revenue, and price forecasts for the Stem Cell Cryopreservation Equipments market, and consumption forecasts for the industry by the application.

Regional Stem Cell Cryopreservation Equipments Market Analysis: It can be divided into two different classes one for regional production analysis and the other for regional consumption analysis. Here, analysts share gross margin, price, revenue, production, CAGR, and other factors that indicate the growth of all the regional markets studied in the report.

Stem Cell Cryopreservation Equipments Market Competition: In this section, the report provides information about competitive conditions and trends including mergers and acquisitions and expansions, market shares of three or five players, and market concentration rates. Readers may also be provided by manufacturers with production, revenue, and average price shares.

>>>Purchase This Report:https://www.worldwidemarketreports.com/buy/562010

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Contact Us:

Mr. Shah Worldwide Market Reports, Tel: U.S. +1-415-871-0703 / U.K. +44-203-289-4040 / Japan +81-50-5539-1737 Email: sales@worldwidemarketreports.com

Read the original:
Stem Cell Cryopreservation Equipments Market Size Report: Strategies of Key Manufacturers, Project Investment of New Industries: Chart, Worthington...

Seattle Cancer Care Alliance Celebrates 20 Years of Innovation in Cancer Treatment and Care – Business Wire

SEATTLE--(BUSINESS WIRE)--Seattle Cancer Care Alliance (SCCA) today marked the 20th anniversary of opening the doors of its first clinic in South Lake Union. Established in 2001 to bring together leading research teams and cancer specialists from Fred Hutchinson Cancer Research Center, Seattle Children's and University of Washington Medicine, SCCA began with a singular mission that remains its focus today: the pursuit of better, longer, richer lives for cancer patients. In the last two decades, its teams have served nearly 190,000 cancer patients and conducted more than 1,700 clinical trials, advancing cancer care not only in the Pacific Northwest but also throughout the nation.

SCCA was founded with the unique vision that combining the best in cancer care and research will change the lives of those with cancer, said Dr. Nancy E. Davidson, president and executive director at SCCA and senior vice president of the Clinical Research Division at Fred Hutch. Throughout the past 20 years, our organization has proven the power of this vision. Our teams have helped drive new advances in the delivery of cancer care as well as the development of cutting-edge new therapies and technologies that have improved how we screen for, diagnose and treat many cancers as well as how we support cancer patients and their loved ones. And while we are proud of what we have accomplished the last 20 years, SCCA is ready to continue to build on this foundation for decades to come.

SCCA opened its first outpatient clinic in Seattles South Lake Union neighborhood in 2001. It has grown from a single location to a network of treatment centers in the Puget Sound region encompassing hematology/medical oncology, radiation oncology and infusion outpatient services. It also has network affiliations with hospitals in five states, connecting community-based physicians with the latest cancer research and treatment options from SCCA to elevate cancer care in the community.

As part of the only National Cancer Institute (NCI)-designated cancer center in Washington state, SCCA has helped to advance cancer research, establish new models of cancer care, connect more cancer patients to clinical trials, and enhance patients access to the best possible cancer care and treatment.

Putting patients first is paramount to everything we do at SCCA. And its because of the commitment and passion of our staff from physicians and nurses to pharmacists and administrative support staff that we have been able to succeed and deliver on that promise, said Aaron Crane, executive vice president at SCCA. Their work has driven SCCA to new heights in cancer care and allowed us to achieve significant growth. With the expected opening of our South Lake Union clinic expansion in 2023, we will be able to conduct more cutting-edge research and provide even more patients world-class cancer care.

SCCA alliance member Fred Hutch is known for its pioneering work in bone marrow (BMT) and stem cell transplantation. Stemming from this legacy work, SCCA is continually recognized for its patients survival rates and has now performed more than 9,000 transplants since 2001, making it among the most experienced cancer centers in this field in the world. SCCA is also noted for its leadership in immunotherapy. In 2016, it opened the Bezos Family Immunotherapy Clinic to support its growing work in this field. This clinic, which has now treated more than 500 patients, has increased the number of clinical trials offering cellular immunotherapies, including CAR-T therapies. SCCA is one of the top providers of CAR-T therapy and among the first cancer centers to offer patients all three FDA-approved cellular immunotherapies.

Through groundbreaking clinical trials, along with alliance partners UW Medicine, Seattle Childrens Hospital and Fred Hutch, SCCA has led the development of new treatment options for patients for a variety of cancers. Over the last two decades, SCCA has opened more than 1,700 trials serving nearly 37,000 participants. A couple of recent examples include a SCCAs trial for a new bladder cancer treatment, which received FDA approval after its results gained international recognition, redefining treatment protocols for that cancer. Another example is a recent clinical trial for lung cancer where SCCA is advancing personalized care through research that assesses the effectiveness of a treatment in real time, allowing providers to give patients treatments based on an individualized care path.

SCCA also has contributed to the development and adoption of molecular testing in cancer care. Its team has expanded known biomarkers that indicate a patients risk for certain cancers including breast, lung and colon cancers and hematologic malignancies as well as determine the best course of treatment. In 2016 and 2018 respectively, SCCA opened the Prostate Cancer Genetics and Hematologic Malignancy Genetics Clinics, which offer genetic testing, counseling, and consultations to help patients better understand their genetic risks and manage their cancers.

SCCA has been a vital part of saving the lives of so many across our region, said Paula Rosput Reynolds, Chair of SCCAs Board of Directors. It has seamlessly combined pioneering research with the best in state-of-the-art clinical patient- and family-centered care. SCCA has made an indelible mark on how many cancers are diagnosed and treated and continues to push boundaries on how cancer care is approached and carried out. We are excited to celebrate its achievements this year and look forward to what is yet to come from this extraordinary organization and its team.

For the past decade, SCCA has also been recognized by U.S. News & World Report as among the Best Cancer Hospitals in the U.S. and the top cancer hospital in the Pacific Northwest.

About Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) brings together the leading research teams and cancer specialists from Fred Hutch, Seattle Childrens and UW Medicine one extraordinary group whose sole purpose is the pursuit of better, longer, richer lives for our patients. Based in Seattles South Lake Union neighborhood, SCCA is the only National Cancer Institute (NCI)-designated cancer center in Washington state. SCCA has nine clinical care sites in the region, including a medical oncology clinic at EvergreenHealth in Kirkland; hematology/medical oncology and infusion services at Overlake Medical Center in Bellevue, medical and radiation oncology clinics at UW Medical Center - Northwest Seattle and medical oncology services at SCCA Issaquah, as well as Network affiliations with hospitals in five states. For more information about SCCA, visit seattlecca.org.

See the original post here:
Seattle Cancer Care Alliance Celebrates 20 Years of Innovation in Cancer Treatment and Care - Business Wire